The Safety and Efficacy of Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma Patients (ASOG-01)
Latest Information Update: 06 Feb 2024
At a glance
- Drugs Adebrelimab (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ASOG-01
- 26 Jan 2024 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 72 to 110. Also the Primary endpoint has been updated and the overall trial focus has been changed to TU.
- 26 Jan 2024 Planned number of patients changed from 72 to 110.
- 26 Jan 2024 Status changed from not yet recruiting to recruiting.